Table 3.
The Total Public Expenditure on OMPs in Euro per Capita in 7 EU Countries in 2013 and 2014
| Austrial | Belgium | Bulgariam | Czech Republicn | Hungary | Poland | Slovenia | |
|---|---|---|---|---|---|---|---|
| 2013 | |||||||
| Total public expenditure on OMPs in local currency | 98,600,000 €a | 245,000,000 €b | 16,201,220 BGNc | 1,100,000,000 CZKd | 9,577,605,323 HUFe | 212,725,536 PLNf | 16,893,308 €g |
| Eurostat exchange rate - annual data (/1 €) | 1.96 BGNh | 25.98 CZKh | 296.87 HUFh | 4.20 PLNh | |||
| Total public expenditure on OMPs in € | 98,600,000 | 245,000,000 | 8266,000 | 42,340,000 | 32,262,000 | 50,649,000 | 16,893,000 |
| Size of population | 8,500,000j | 11,161,642i | 7,284,552i | 10,516,125i | 9,908,798i | 38,062,535i | 2,058,821i |
| Total public expenditure on OMPs in €/capita | 11.60 | 21.95 | 1.13 | 4.03 | 3.26 | 1.33 | 8.21 |
| 2014 | |||||||
| Total public expenditure on OMPs in local currency | 109,800,000 €a | 280,000,000 €b | 23,967,183 BGNc | 1,400,000,000 CZKo | 12,501,994,171 HUFe | 348,368,792PLNf | 19,853,716 €g |
| Eurostat exchange rate - annual data (/1 €) | 1.96 BGNh | 27.54 CZKh | 308.71 HUFh | 4.18 PLNh | |||
| Total public expenditure on OMPs in € | 109,800,000 | 280,000,000 | 12,228,000 | 50,835,000 | 40,496,000 | 83,342,000 | 19,854,000 |
| Size of population | 8,500,000k | 11,180,840i | 7,245,677i | 10,512,419i | 9,877,365i | 38,017,856i | i2,061,085 |
| Total public expenditure on OMPs in €/capita | 12.92 | 25.04 | 1.69 | 4.84 | 4.10 | 2.19 | 9.63 |
| Average of total expenditure on OMP in €/capita in 2013 and 2014 | 12.26 | 23.50 | 1.41 | 4.43 | 3.68 | 1.76 | 8.92 |
Sources: a Federation of Austrian Social Insurance Institutions (Hauptverband der österreichischen Sozialversicherungsträger)
bNational Institute for Health and Disability Insurance of Belgium (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor ziekte-en invaliditeitsverzekering, INAMI / RIZIV)
cNational Health Insurance Fund of Bulgaria, National Council on Prices and Reimbursement of Medicinal Products
dState Institute for Drug Control (Státní ústav pro kontrolu léčiv, SUKL)
e National Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
fNational Health Fund (Narodowy Fundusz Zdrowia), Ministry of Health (Ministerstwo Zdrowia)
g Health Insurance Institute of Slovenia (Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
h http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ert_bil_eur_a&lang=en
ihttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_gind&lang=en
jAustrian data was not available on Eurostat database, the source: https://data.oecd.org/pop/population.htm
kAustrian data was not available on Eurostat or OECD database, the calculated number was taken from the previous year
lOrphan drug expenditure in hospitals not included
mThese data was based on 10 OMs reimbursed by National Health Insurance Fund
nAdditional drugs were identified which held orphan designation until 2013/14 with significant costs (Glivec, Ilaris, Ventavis)
oData was not available at time of data request; this number assumes same total expenditure on public healthcare as in year 2013